2/2
12:58 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
12:47 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
2/2
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
11:36 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
11:36 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:33 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:33 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:23 am
regn
Rating for REGN
Low
Report
Rating for REGN
1/22
10:32 am
regn
Rating for REGN
Low
Report
Rating for REGN
1/7
08:02 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.
12/12
12:18 pm
regn
Rating for REGN
Low
Report
Rating for REGN
12/12
12:18 pm
regn
Rating for REGN
Low
Report
Rating for REGN
12/10
03:06 pm
regn
Rating for REGN
Low
Report
Rating for REGN
12/10
03:06 pm
regn
Rating for REGN
Low
Report
Rating for REGN
12/4
02:00 pm
regn
Rating for REGN
Low
Report
Rating for REGN
12/4
09:00 am
regn
Rating for REGN
Low
Report
Rating for REGN
12/4
09:00 am
regn
Rating for REGN
Low
Report
Rating for REGN
12/3
10:27 am
regn
Rating for REGN
Low
Report
Rating for REGN
12/3
10:27 am
regn
Rating for REGN
Low
Report
Rating for REGN
12/3
08:44 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
12/3
08:44 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $767.00 price target on the stock.
12/3
05:05 am
regn
Regeneron downgraded to Equal Weight from Overweight at Morgan Stanley
Low
Report
Regeneron downgraded to Equal Weight from Overweight at Morgan Stanley
12/3
05:05 am
regn
Regeneron downgraded to Equal Weight from Overweight at Morgan Stanley
Low
Report
Regeneron downgraded to Equal Weight from Overweight at Morgan Stanley
11/24
10:01 am
regn
Rating for REGN
Low
Report
Rating for REGN